Literature DB >> 32277648

Berberine inhibits human gastric cancer cell growth via deactivation of p38/JNK pathway, induction of mitochondrial-mediated apoptosis, caspase activation and NF-κB inhibition.

Yue Wang1, Mingyin Zhou, Dong Shang.   

Abstract

PURPOSE: Gastric cancer accounts for considerable mortality across the globe. In this study the anticancer effects of a natural compound Berberine were investigated in vitro. Effects of berberine on cell migration, cellular apoptosis, Nf-kB and JNK/p38 signalling pathways were also studied.
METHODS: The cell viability of SNU-1 gastric cancer cells after berberine treatment was evaluated by CCK-8 assay, while the effects on cell migration were checked by wound healing assay. Effects on cellular apoptosis were evaluated by fluorescence microscopy using DAPI staining, as well as using flow cytometry with annexin V/propidium iodide (PI) staining. Effects on apoptosis-related protein expressions were checked by western blot method.
RESULTS: The results showed that Berberine decreased the viability of the gastric cancer SNU-1 cells and exhibited an IC50 of 30 µM. The cytoxicity of Berberine was also investigated on the normal GES-1 gastric cells and it was found that Berberine exerted very low toxic effects on these cells and exhibited an IC50 of 120 µM. Berberine also caused remarkable changes in the morphology of the SNU-1 cells. PI and DAPI staining revealed that Berberine prompted apoptosis of the SNU-1 cells in a dose-dependent manner. The apoptotic cells increased from 2.2% in control to around 35% at 30 µM concentration. Berberine also suppressed the migration and invasion of the gastric cancer cells via blocking of the JNK/p38 signalling pathway.
CONCLUSIONS: Berberine may act as a promising drug candidate for gastric cancer as demonstrated from the current study.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32277648

Source DB:  PubMed          Journal:  J BUON        ISSN: 1107-0625            Impact factor:   2.533


  8 in total

1.  Modulation of TLR/NF-κB/NLRP Signaling by Bioactive Phytocompounds: A Promising Strategy to Augment Cancer Chemotherapy and Immunotherapy.

Authors:  Sajad Fakhri; Seyed Zachariah Moradi; Akram Yarmohammadi; Fatemeh Narimani; Carly E Wallace; Anupam Bishayee
Journal:  Front Oncol       Date:  2022-03-01       Impact factor: 6.244

2.  Nicotinic receptors modulate antitumor therapy response in triple negative breast cancer cells.

Authors:  Alejandro Español; Yamila Sanchez; Agustina Salem; Jaqueline Obregon; Maria Elena Sales
Journal:  World J Clin Oncol       Date:  2022-06-24

Review 3.  Berberine, a Herbal Metabolite in the Metabolic Syndrome: The Risk Factors, Course, and Consequences of the Disease.

Authors:  Anna Och; Marek Och; Renata Nowak; Dominika Podgórska; Rafał Podgórski
Journal:  Molecules       Date:  2022-02-17       Impact factor: 4.411

Review 4.  The Potential Anticancer Activity of Phytoconstituents against Gastric Cancer-A Review on In Vitro, In Vivo, and Clinical Studies.

Authors:  Sylwia Nakonieczna; Aneta Grabarska; Wirginia Kukula-Koch
Journal:  Int J Mol Sci       Date:  2020-11-05       Impact factor: 5.923

5.  Berberine Improves Chemo-Sensitivity to Cisplatin by Enhancing Cell Apoptosis and Repressing PI3K/AKT/mTOR Signaling Pathway in Gastric Cancer.

Authors:  Yingying Kou; Bending Tong; Weiqing Wu; Xiangqing Liao; Min Zhao
Journal:  Front Pharmacol       Date:  2020-12-09       Impact factor: 5.810

6.  Upregulating miR-637 aggravates endoplasmic reticulum stress-induced apoptosis in gastric cancer cells by suppressing Calreticulin.

Authors:  Qingli Kong; Zhisheng Zhang; Zhipeng Liang
Journal:  Anim Cells Syst (Seoul)       Date:  2020-09-10       Impact factor: 1.815

Review 7.  Biological Activity of Berberine-A Summary Update.

Authors:  Anna Och; Rafał Podgórski; Renata Nowak
Journal:  Toxins (Basel)       Date:  2020-11-12       Impact factor: 4.546

8.  Effects of Berberine on Circular RNA Expression Profiles in Human Gastric Cancer Cells.

Authors:  Meng Wang; Letao Sun; Li Wang; Yongning Sun
Journal:  Evid Based Complement Alternat Med       Date:  2021-05-04       Impact factor: 2.629

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.